Lang Qingata

PreclinicalSmall molecule

Lang Qingata is one of 23 small molecule programs targeting Non-Alcoholic Steatohepatitis. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Non-Alcoholic SteatohepatitisActive, not recruiting

Non-Alcoholic SteatohepatitisPreclinical

Active, not recruiting

Competition

Competitive Landscape

24 competitors in Non-Alcoholic Steatohepatitis

#DrugCompanyPhaseTrials

Actos

Takeda

Approved

3 2

Estrace

Aldactone

Rifadin

Mounjaro

Cytotec

Januvia

ZZydus Therapeutics Inc.

Approved

1 8

Trental

VValidus Pharmaceuticals

Approved

1 9

Ozempic

Novo Nordisk

Phase 3

4 10

Diflucan

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Approved

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Non-Alcoholic Steatohepatitis1 trial

A Multicenter, Double-blind, Placebo-randomized Controlled Clinical Study on the Treatment of Non-alcoholic Steatohepatitis With Tibetan Drug Langqing Atar

Recruiting·SShupei Li·N/A·NCT06193629·150 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Lang Qingata. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Lang Qingata compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Lang Qingata. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Shupei Li company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: SShupei Li

Lang Qingata

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Non-Alcoholic Steatohepatitis1 trial

References

Drug Info

Quick Facts

Related News